SRTSSensus Healthcare Inc

Sensus Healthcare (NASDAQ:SRTS) will be releasing its Q1 2026 earnings after the market closes on Thursday, May 7. (View Earnings Report at...

Sensus Healthcare (NASDAQ:SRTS) Stock Passes Below Fifty Day Moving Average - Time to Sell...

Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced...

Sensus Healthcare, Inc. (NASDAQ:SRTS - Get Free Report) has earned a consensus rating of "Moderate Buy" from the six ratings firms that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned...

Sensus Healthcare, Inc. (NASDAQ:SRTS - Get Free Report) saw a large decrease in short interest in March. As of March 13th, there was short interest totaling 394,950 shares, a decrease of 18.3% from the February 26th total of 483,655 shares. Currently, 2.6% of the company's shares are sold short...

Shares of Sensus Healthcare, Inc. (NASDAQ:SRTS - Get Free Report) have been given an average rating of "Moderate Buy" by the six analysts that are currently covering the firm, MarketBeat.com reports...

Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced the filing of a lawsuit in the Circuit Court for the Fifteenth...

Alliance Global Partners started coverage on Sensus Healthcare in a research report on Friday. They set a "buy" rating and a $7.50 price target for the company...

Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological...